Dioscin Ameliorates Experimental Autoimmune Thyroiditis via the mTOR and TLR4/NF-κB Signaling
Chengfei Zhang,Qiue Zhang,Lingling Qin,Zhiyi Yan,Lili Wu,Tonghua Liu
DOI: https://doi.org/10.2147/DDDT.S410901
2023-08-03
Abstract:Chengfei Zhang, 1, 2, &ast Qiue Zhang, 3, &ast Lingling Qin, 4, &ast Zhiyi Yan, 5 Lili Wu, 4, 5 Tonghua Liu 5 1 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 2 Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, People's Republic of China; 3 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 4 Technology Department, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 5 Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tonghua Liu, Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, People's Republic of China, Email Background: Autoimmune thyroiditis (AIT) is a common autoimmune disease that causes thyroid dysfunction. Clinical symptoms in Hashimoto thyroiditis patients were improved after oral administration of dioscin. However, the mechanisms involved in the therapeutic effect remain unclear. Methods: The protective effects and potential mechanisms of dioscin for autoimmune thyroiditis were explored in a rat model of thyroglobulin-induced autoimmune thyroiditis. Firstly, the rat model of AIT was obtained by subcutaneous injection of thyroglobulin and drinking the sodium iodide solution, followed by gavage administration for 8 weeks. Rats were sacrificed after anaesthesia, serum and thyroid samples were preserved. Serum triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibody (TRAb) expressions were measured by enzyme-linked immunosorbent assay (ELISA). Morphological changes were observed by H&E staining. Next, we used transcriptomics techniques to find the potential therapeutic target of dioscin. Finally, we validated the transcriptomic results by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC-P), respectively. Results: Animal experiments showed that dioscin regulated T3, T4, FT3, TSH, TgAb, TPOAb, and TRAb and alleviated the pathological process in a dose-dependent manner, with the high-dose group showing optimal efficacy. In the transcriptome, the nuclear factor kappa B (NF-κB) pathway was identified by KEGG enrichment analysis and validated by RT-PCR and IHC-P. The relative expression of NF-κB, mechanistic target of rapamycin (mTOR), and toll-like receptor 4 (TLR4) mRNA and protein were decreased in the dioscin-treated group compared to the AIT model group. Conclusion: Our results suggest that dioscin treatment improved thyroid function and downregulated TGAb, TPOAb and TRAb levels in rat models of AIT, which may alleviate the pathological process and suppress the inflammatory response by inhibiting mTOR and TLR4/NF-κB pathways. Graphical Keywords: dioscin, autoimmune thyroiditis, transcriptome, TLR4/NF-κB Graphical Autoimmune thyroiditis refers to an organ-specific autoimmune disease characterised by structural destruction of thyroid tissue and hypothyroidism caused by lymphocyte-infiltrating autoantibodies (TPOAb and TgAb) in the thyroid tissue. 1 High titers of TgAb are present in most patients with AIT (40%-70%), and more than 80% of patients with AIT have high titers of TPOAb. 2 In general, the diagnosis can be confirmed by thyroid ultrasound and antibody testing in clinical practice. The prevalence of AIT is increasing year by year and is much higher in women than in men. 3 The pathogenesis of AIT is unclear and may be related to genetic susceptibility, environmental factors, and endogenous factors. Their interaction leads to the destruction of immune tolerance, the production of thyroid autoantigens and to the subsequent activation of T lymphocytes, which induce lymphocyte migration to the thyroid and produce anti-thyroid autoantibodies. 4 Currently, there are no specific treatment options for AIT, which are limited and carry a high risk of serious side effects, including surgical treatment, thyroid hormone therapy or immunomodulatory therapy. Therefore, there is an urgent need to find a new effective and safe drug for AIT. Dioscin is a natural steroidal saponin extracted from the roots of the Dioscorea plants, Dioscorea nipponica and Dioscorea zingibe -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal